Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

18 years - 99 years
All genders
Phase 1
Interventional
This research study consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be …
Learn More
Intramolecular Imaging with ICG (PRIME)

Intramolecular Imaging with ICG (PRIME)

18 years - 99 years
All genders
Phase 2
Interventional
The purpose of this protocol is to monitor the rate of recurrence in patients who undergo cancer surgery. Patient diagnosed with solid tumor cancers have a high rate of recurrence when surgery is a treatment. The high rates of recurrence suggest that surgeons are unable to completely detect and remove …
Learn More
Understanding COVID-19 vaccine responses in the setting of immunotherapy (Sub-study)

Understanding COVID-19 vaccine responses in the setting of immunotherapy (Sub-study)

18 years - 99 years
All genders
This research is a sub-study to the “Understanding influenza vaccine responses in the setting of immunotherapy” protocol (parent study). This sub-study is open to only those participants that have consented to be part of the above parent study. This study is designed to better understand antibody responses in the setting …
Learn More
CHARM- Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction

CHARM- Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction

18 years - 99 years
All genders
Phase 3
Interventional
This is a Phase 3 study, which means that BIIB093 (study drug) has already been investigated in previous clinical research studies with a small number of people with large hemispheric infarction (LHI). These studies suggested that the study drug was safe, did not cause serious side effects or discomfort, and …
Learn More
DREAMM 2

DREAMM 2

18 years - 99 years
All genders
Phase 2
This research study is being done to learn more about multiple myeloma and if the study drug, GSK2857916, can improve multiple myeloma in patients who have already failed other treatments.
Learn More
Undiagnosed Diseases Network- Clinical and Genetic Evaluation of Patients with Undiagnosed Disorders

Undiagnosed Diseases Network- Clinical and Genetic Evaluation of Patients with Undiagnosed Disorders

18 years - 99 years
All genders
We are doing this research study to improve diagnosis and care for people with undiagnosed diseases. We are asking you to take part in this research study because you have an undiagnosed disease. About 8000 people will take part over the entire course of this research study. The NIH is …
Learn More
FALCON- TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

FALCON- TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

18 years - 70 years
All genders
Phase 3
Autosomal dominant polycystic kidney disease (ADPKD) is a multi-organ disorder that results in clusters of fluid-filled cysts in the kidneys and other organs leading to progressive enlargement and loss of organ function. ADPKD is a genetic disorder caused by mutations in the PKD1 and PKD2 genes, which encode the proteins …
Learn More
ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA

ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA

18 years - 99 years
All genders
Purpose is to determine if cemiplimab (given as infusion in the vein) will prevent cutaneous squamous cell cancer from returning after surgery and radiation. Subjects at least 18 years of age who have had surgery and radiation therapy for cutaneous squamous cell cancer, and there is a risk that this …
Learn More
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

18 years - 99 years
Female
Observational
This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer or vincristine for lymphoma. Participants will be enrolled over approximately 1-year.The purpose of this present study is to prospectively collect clinical and biomarker data from patients receiving neurotoxic chemotherapy who …
Learn More
RhIMAB Study

RhIMAB Study

18 years - 99 years
All genders
Participation in this research study is presented as a voluntary option to those women presenting at Penn Medicine and choosing medication abortion. The research team seeks to asses the value of blood typing and the provision of Rh immune globulin to women choosing medication abortion at 10 weeks and 0 …
Learn More
961 - 970 of 1243